- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03955887
Mitochondrial Dysfunction of Alveolar and Circulating Immune Cells During Acute Respiratory Distress Syndrome: Impact of Infectious Aggression and Alveolar Stretching as a Result of Mechanical Ventilation. (PNEUMOCHONDRIE)
Sepsis leads to a deregulated host response that can lead to organ failure. During sepsis, experimental and clinical data suggest the occurrence of mitochondrial dysfunctions, particularly in circulating muscle and monocytes, which may contribute to organ failure and death.
Lower respiratory infection is the leading cause of death from infectious causes. Mechanical ventilation (MV) is required in 20% of cases of bacterial pneumopathy with Streptococcus pneumoniae (S.p.) , with mortality reaching 50%. There are then frequently criteria for acute respiratory distress syndrome (ARDS), combining bilateral lung involvement and marked hypoxemia.
Cyclic stretching of lung cells induced by MV causes sterile inflammation and tissue damage (i.e. ventilator-induced lung injury [VILI]), which can cause cellular dysfunction that alter the immune response, particularly during ARDS. This is why the application of a so-called protective MV is then required. However, this does not prevent about one-third of patients from showing signs of alveolar overdistension, as evidenced by an increase in motor pressure (MP) (MP≥ 15 cmH2O), associated with an increase in mortality.
The deleterious effects of MV could be explained by the occurrence of mitochondrial abnormalities. Indeed, the cyclic stretching of lung cells leads to dysfunction in the respiratory chain and the production of free oxygen radicals (FOS), altering membrane permeability. These phenomena could promote VILI, facilitate the translocation of bacteria from the lung to the systemic compartment and lead to alterations in immune response.
In our model of S.p. pneumopathy in rabbits, animals on MV develop more severe lung disorders (lack of pulmonary clearance of bacteria, bacterial translocation in the blood, excess mortality), compared to animals on spontaneous ventilation (SV). Intracellular pulmonary mitochondrial DNA (mtDNA) concentrations, a reflection of the mitochondrial pool, are significantly decreased in ventilated rabbits compared to SV rabbits and in infected rabbits compared to uninfected rabbits. At the same time, the mitochondrial content of circulating cells decreased early (H8) in all infected rabbits, but was only restored in rabbits in SV, those who survived pneumonia (Blot et al, poster ECCMID 2015, submitted article). These data suggest an alteration in the mechanisms that restore mitochondrial homeostasis (mitochondrial biogenesis and mitophagy) during the dual infection/MV agression, which may explain the observed excess mortality. Other work by our team illustrates the importance of these phenomena by showing in a mouse model of polymicrobial infection that inhibition of mitophagia in macrophages promotes survival (Patoli et al, in preparation). Human data on this subject are non-existent.
The phenomena of mitochondrial dysfunction nevertheless deserve to be explored in humans during the combined MV/pneumopathy aggression in order to understand its possible impact on the effectiveness of the host's immune response. In a personalized medicine approach, these data would open up prospects for targeted therapies, capable of activating mitochondrial biogenesis and/or modulating mitophagia, to prevent organ dysfunction and mortality during severe CALs treated with antibiotic therapy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Mathieu Blot
- Phone Number: +33 03 80 29 33 05
- Email: mathieu.blot@chu-dijon.fr
Study Locations
-
-
-
Dijon, France, 21000
- Chu Dijon Bourogne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient who has given his non-opposition (or non-opposition obtained from close relative of ventilated patients, who will be informed as soon as possible).
- Adult patient
Group 1: patient with:
Acute pneumonitis defined by: Signs and acute symptoms of pneumonia (new or worsening within the last 7 days), at least 2 of which are:
- Coughing
- Purulent sputum
- Dyspnea
- Chest pain
- Temperature < 35°C or ≥ 38°C And a new pulmonary radiological infiltrate (x-ray or CT scan on admission)
- Not acquired under mechanical ventilation
- Complicated from ARDS according to the new Berlin definition, Chest x-ray finding bilateral parenchymal opacities not fully explained by pleural effusions, nodules or atelectasis. Respiratory distress not explained by cardiac dysfunction or overfilling. An echocardiogram will be performed in case of diagnostic uncertainty. PaO2/FiO2 report < 300 and PEP ≥ 5 cmH2O
- Requiring the use of MV.
- With a diagnostic BAL performed within 72 hours of the start of the MV
Group 2: Patients:
- No fever during the last 15 days (reported or measured ≥ 37.8°C).
- Not under MV,
- Undergoing BAL for a reason other than acute infection (e.g. chronic interstitial syndrome, nodule or lung mass).
Exclusion Criteria:
- Patient not affiliated to the national health insurance system
- Major under judicial protection
- Pregnant, parturient or breastfeeding woman
- Known primary or secondary immune deficiency (radiotherapy, chemotherapy, immunosuppressive therapy or systemic corticosteroid therapy (>10mg/day prednisone equivalent for more than 7 days) within 6 months before inclusion, HIV infection, primary cellular immune deficiency)
- Patients with treatment known to modulate mitochondrial function, biogenesis and/or mitophagia (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, metformin, sildenafil)
- Patients with pulmonary fibrosis or cystic fibrosis known to be associated with mitochondrial alterations
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Experimental
Patients with severe acute lung disease requiring mechanical ventilation
|
Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
|
Control
Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection
|
Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Active mitochondria content of alveolar macrophages
Time Frame: Through study completion, an average of 19 months
|
Through study completion, an average of 19 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Respiratory Tract Diseases
- Respiration Disorders
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Aggression
- Lung Diseases
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Dimercaprol
Other Study ID Numbers
- BLOT MSD-APJ 2018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Diseases
-
Aveiro UniversityFundação para a Ciência e a TecnologiaNot yet recruitingInterstitial Lung DiseasesPortugal
-
RWTH Aachen UniversityCompletedObstructive Lung DiseasesGermany
-
Guangzhou Institute of Respiratory DiseaseUnknownInterstitial Lung Disease | Transbronchial Lung Cryobiopsy | Surgical Lung Biopsy
-
China-Japan Friendship HospitalXiangya Hospital of Central South University; Peking Union Medical College... and other collaboratorsUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedInterstitial Lung DiseasesNetherlands
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
Shanghai East HospitalRegend TherapeuticsCompletedInterstitial Lung DiseasesChina
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaRecruitingInterstitial Lung Diseases (ILD)Portugal
-
China-Japan Friendship HospitalNot yet recruitingTransbronchial Lung Cryobiopsy
Clinical Trials on bronchoalveolar lavage fluid (BAL)
-
Vanderbilt University Medical CenterNational Institute of General Medical Sciences (NIGMS)TerminatedVentilator Associated Pneumonia (VAP)United States
-
Universitätsmedizin MannheimCompletedPneumonia | Interstitial Lung Disease | Malignant Neoplasm
-
University of AthensAcademy of AthensCompletedAcute Respiratory Distress Syndrome | Ventilator-Associated PneumoniaGreece
-
Tetraphase Pharmaceuticals, Inc.PRA Health SciencesCompletedHealthy SubjectsUnited Kingdom
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases, Obstructive | Pulmonary Disease, Chronic ObstructiveUnited States
-
Hannover Medical SchoolUnknownParanasal Sinus Diseases | Cystic Fibrosis | LungtransplantationGermany
-
McGill University Health Centre/Research Institute...McGill UniversityRecruitingRheumatic Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Interstitial Lung Disease | Usual Interstitial Pneumonia | Nonspecific Interstitial Pneumonia | Rheumatic Arthritis | Systemic Autoimmune Disease | Autoimmune MyositisCanada
-
Brno University HospitalSt. Anne's University Hospital Brno, Czech RepublicRecruitingCOVID-19 Pneumonia | ARDS, Human | SuperinfectionCzechia
-
Postgraduate Institute of Medical Education and...CompletedBronchoalveolar Lavaage | Diffuse Lung DiseaseIndia
-
Masonic Cancer Center, University of MinnesotaTerminatedCytokine Release Syndrome | Immune and Microbial Reconstitution | Systemic Viral Infection | Acute-graft-versus-host Disease | Chronic Graft-versus-host-disease | Recurrent Malignancy | Allogenic Related Donors | Cell Therapy/Immunotherapy PatientsUnited States